Bristol Myers Squibb stock broadens AI strategy with Pathos deal

Published on 11/04/2026 at 16:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol Myers Squibb stock gains a broader AI and data angle in neuroscience research through its Pathos collaboration. The deal targets Alzheimer's development.

AI Deal Expands Neuroscience Strategy

Pathos and Bristol Myers Squibb are combining artificial intelligence, neurological patient data and drug-development expertise.
The collaboration gives BMS broader access to Pathos Foundry and defined exclusive rights in neuroscience.
The financing supports Pathos's clinical pipeline, including the JSKN016 antibody-drug conjugate.

Bristol Myers Squibb, US1101221083, Illustration mit AI erstellt.

Bristol Myers Squibb is deepening its neuroscience strategy through a collaboration with Pathos AI and Tempus AI announced on October 23, 2026. Pathos says the arrangement combines artificial intelligence, longitudinal patient data and BMS drug-development expertise to support Alzheimer's research and other neurological programs.

Data And AI Extend Pipeline Reach

Under the agreements, Tempus will build a de-identified dataset covering hundreds of thousands of patients with neurological conditions. Pathos will license access to that dataset for five years at a cost of 55 million US dollars and use its Foundry platform to study disease progression, test biological hypotheses and help shape more targeted clinical trials, according to Pathos AI.

BMS receives non-exclusive strategic access to Pathos Foundry across its broader research and development portfolio. In neuroscience, Bristol Myers Squibb secured three-year exclusive rights to support its development programs. The arrangement is intended to improve disease understanding, patient selection and clinical-trial design, but it does not provide clinical efficacy data or a launch timetable for a resulting therapy.

Financing Links BMS To Clinical Pipeline

Bristol Myers Squibb led Pathos AI's 237 million US dollar Series E financing, which valued Pathos at approximately 3 billion US dollars after the round. Pathos said the capital will expand its AI platform and advance four clinical assets, including JSKN016, a TROP2/HER3 bispecific antibody-drug conjugate headed toward registrational studies.

Bristol Myers Squibb stock traded at 55.60 euros on Lang & Schwarz at 16:30 CET on Wednesday, November 4, 2026. Investors can follow the real-time quote of Bristol Myers Squibb stock.